Costagliola D - Search Results

1

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), et al. Among authors: costagliola d. J Infect Dis. 2013 Mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225900

2

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.

Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Phillips AN, et al. Among authors: costagliola d. AIDS. 1999 Oct 22;13(15):2075-82. doi: 10.1097/00002030-199910220-00010. AIDS. 1999. PMID: 10546860

3

Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.

Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. Salmon-Céron D, et al. Among authors: costagliola d. AIDS. 2000 May 26;14(8):1041-9. doi: 10.1097/00002030-200005260-00017. AIDS. 2000. PMID: 10853987 Clinical Trial.

4

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Grabar S, et al. Among authors: costagliola d. Ann Intern Med. 2000 Sep 19;133(6):401-10. doi: 10.7326/0003-4819-133-6-200009190-00007. Ann Intern Med. 2000. PMID: 10975957

5

Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.

Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Among authors: costagliola d. J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8. doi: 10.1097/00042560-200102010-00007. J Acquir Immune Defic Syndr. 2001. PMID: 11242182

6

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: costagliola d. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.

7

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: costagliola d, d arminio monforte a. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821

8

Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.

del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E; French Hospital Database on HIV Clinical Epidemiologic Group. del Giudice P, et al. Among authors: costagliola d. J Infect Dis. 2002 Nov 1;186(9):1366-70. doi: 10.1086/344325. Epub 2002 Oct 11. J Infect Dis. 2002. PMID: 12402211

9

Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.

Gourlain K, Salmon D, Gault E, Leport C, Katlama C, Matheron S, Costagliola D, Mazeron MC, Fillet AM; Predivir Study Group; CMV AC11 Study Group. Gourlain K, et al. Among authors: costagliola d. J Med Virol. 2003 Mar;69(3):401-7. doi: 10.1002/jmv.10303. J Med Virol. 2003. PMID: 12526052

10

Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures.

Thiébaut R, Jacqmin-Gadda H, Leport C, Katlama C, Costagliola D, Le Moing V, Morlat P, Chêne G; APROCO Study Grooup. Thiébaut R, et al. Among authors: costagliola d. J Biopharm Stat. 2003 May;13(2):271-82. doi: 10.1081/BIP-120019271. J Biopharm Stat. 2003. PMID: 12729394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

731 results

Search Page

Filters